ArticlePloS one2026
Proteomics-based biomarkers of plasma exosomes from patients with acute myocardial infarction.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to identify plasma exosomal protein biomarkers for early recognition of acute myocardial infarction (AMI) using label-free quantitative proteomics.
methodsPatients presenting to the Second Affiliated Hospital of Soochow University with chest discomfort between February 2022 and December 2022 were enrolled. Plasma exosomes from a discovery cohort (six AMI patients and six non-AMI controls) were analyzed by mass spectrometry. Differentially expressed proteins (DEPs) were subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Candidate proteins were further validated by western blot (WB) in an independent validation cohort (20 AMI patients and 20 non-AMI controls). Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic potential of the DEPs for AMI.
resultsA total of 24 DEPs were identified, of which 11 were upregulated and 13 were downregulated in AMI patients. WB analysis confirmed the significantly elevated expression of Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) in AMI-derived exosomes. The area under the ROC curve (AUC) for ITIH4 was 0.8825, indicating high diagnostic accuracy. Correlation analysis revealed a significant positive correlation between plasma exosomal ITIH4 levels and the level of cTnI expression (R = 0.702, P < 0.001), indicates that exosomal ITIH4 may serve as a novel acute-phase reactant during myocardial injury.
conclusionPlasma exosomal ITIH4 is closely associated with AMI and may serve as a promising early diagnostic biomarker.
trial registrationRegistered at the Chinese Clinical Trial Registry (https://www.chictr.org.cn/showproj.html?proj=149623) with No. ChiCTR2200056343 on February 4, 2022. Principal investigator: Jiang Zhu.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.